Bristol Myers Squibb Company is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's mission is to provide transformative therapies in areas such as oncology, immunology, and cardiovascular disease. Bristol Myers Squibb employs a strategy focused on scientific excellence and collaboration, leveraging cutting-edge research and development to address unmet medical needs. Through its robust pipeline and commitment to patient access, the company aims to improve health outcomes and enhance the quality of life for patients worldwide.

BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb (BMS) continues to make significant strides in the oncology sector, particularly with its CAR T-cell therapy, Breyanzi (liso-cel). Recently approved for NHS use in England for aggressive large B-cell lymphoma, Breyanzi offers a new treatment avenue for patients, demonstrating improved outcomes over standard care. Priced at £297,000, this...

Bristol-Myers Squibb's Breyanzi CAR T-Cell Therapy Gains NHS Approval While Facing Challenges with Opdualag and Collaborations to Enhance Oncology Portfolio

Bristol-Myers Squibb's Breyanzi CAR T-Cell Therapy Gains NHS Approval While Facing Challenges with Opdualag and Collaborations to Enhance Oncology Portfolio

Bristol-Myers Squibb is making waves in oncology with the NHS approval of Breyanzi for aggressive large B-cell lymphoma, showcasing its innovative edge. But with challenges looming for Opdualag and the complexities of market competition, can BMS navigate this evolving landscape successfully?